RSV
Advertisement
Dr. Shaun Grannis talks about a large-scale study which showed the robust efficacy of RSV vaccine in older adults.
A cross-sectional study aimed to assess RSV rates before the 2023 vaccine introduction.
The index date marked the start of the respiratory episode that involved hospitalization or a diagnosis of RSV or flu.
Researchers compared four RSV seasons, two before and two during the COVID-19 pandemic.
Preliminary data highlight the potential of rAAV5 vectors in RSV immunity.
Public worry about contracting RSV has appreciably dropped in the past year, though not worry about COVID-19 or seasonal flu.
RSV vaccination is effective at preventing hospitalizations and trips to the emergency room in older adults.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.